BioSpace News Archive

The New England Journal of Medicine publishes CTX001 manuscript containing the first report of investigational use of CRISPR/Cas9-based gene editing to treat inherited diseases in humans

AbbVie announced new data from the Phase 2 CAPTIVATE clinical trial evaluating IMBRUVICA® in combination with VENCLEXTA®/VENCLYXTO® in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma during an oral presentation session at the virtual 2020 American Society of Hematology Annual Meeting.

Superiority head-to-head Phase 3 trial of LOXO-305 vs. investigator’s choice of covalent BTK inhibitor in relapsed-refractory mantle cell lymphoma to be initiated in Q1 2021

New data from the double-blind, placebo-controlled, randomized phase of the Phase 2 CAPTIVATE study presented at ASH 2020 showed that 95 percent of patients with undetectable minimal residual disease randomized to discontinue active treatment after twelve cycles of treatment with IMBRUVICA® plus venetoclax were disease-free and alive, supporting a fixed duration treatment approach

Longer-term data from Phase 1 CRB-401 study evaluating ide-cel in relapsed and refractory multiple myeloma show ongoing deep and durable responses and median overall survival of 34.2 months

Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients

Long-term follow-up data from the Phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta plus Rituxan

Additional data, including EEG findings, support prior initial indications of activity and there were no new adverse events

9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses

Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile